Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + GEMOX for neoadjuvant and conversion therapy in biliary tract cancer
ChiCTR2600132968Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ivonescimab, gemcitabine and oxaliplatin in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer (2 cohorts), sponsored by Peking Union Medical College Hospital. Primary endpoints: Surgical R0 resection rate and Objective response rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ivonescimabgemcitabineoxaliplatin
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2600132968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132968.